BioResearch Monitors Clinical Quality Assurance Audits and Regulatory Compliance Services for Pharmaceutical Research and Development

GCP quality assurance audits and regulatory compliance consulting for pharmaceutical research and development are the principal services offered by BioResearch Monitors. Since 1992, BioResearch Monitors has been a leading independent provider of research-related quality assurance audit and consulting services.

Our clients include major and emerging pharmaceutical and biotechnology companies, CROs and related organizations sponsoring and/or conducting worldwide research within the purview of the FDA’s Bioresearch Monitoring Program, ICH Good Practice guidelines and related multinational GxP quality standards.

GCP quality assurance and regulatory compliance for pharmaceutical research

BioResearch Monitors is dedicated to ensuring data quality and regulatory compliance in all phases of pharmaceutical research. The directors of BioResearch Monitors have been managing and conducting quality assurance operations since the inception of the FDA’s Bioresearch Monitoring Program. Our quality assurance associates are all highly qualified, with advanced degrees and significant, relevant industry and/or medical experience.

BioResearch Monitors prides itself on being flexible to meet the unexpected needs of its clients, and will do everything possible to meet tight project timelines and accommodate unplanned / unexpected ‘For Cause’ audits that need to be performed as soon as possible. BioResearch Monitors has conducted audits in many developing countries and is experienced in dealing with different cultures.

Clinical quality assurance audits

Clinical quality assurance audits, performed to ensure that scientific and ethical standards are met in the conduct of clinical trials, are conducted using proprietary computerized audit tools, customized to each project, so that GCP audit findings can be efficiently and consistently collected, analyzed and reported.

This focused systems-oriented approach to quality assurance is designed to assess and validate study conduct and documentation to ensure regulatory compliance and conformance to protocol, SOP and contractual requirements. Our methodology fully evaluates the activities and documentation underlying study data integrity and Good Clinical Practice (GCP) ethical and regulatory requirements.

To maintain independence and objectivity in performing quality assurance evaluations, BioResearch Monitors does not conduct or manage clinical trials, thereby providing our clients with unbiased opinions, free from any conflicts of interest, when sensitive investigations of internal systems or evaluations of other clinical service providers are needed.

GCP audit and consulting services

GCP audit and consulting services for domestic and worldwide clinical quality assurance include, but are not limited to:

  • Clinical investigator site audits
  • IRB audits
  • CRO and SMO audits
  • Clinical and bioanalytical laboratory audits
  • Central electrophysiology and imaging laboratory audits
  • EDC, data management and data validation audits
  • Study file and regulatory documentation reviews
  • Drug accountability and reconciliation audits
  • Database, final report and regulatory submission audits
  • Computer systems validation audits
  • Preparation of sponsor / monitor and clinical investigator sites for regulatory inspection
  • Training of quality assurance and clinical research personnel
  • Development and review of standard operating procedures
  • Adjunct clinical trial coordination and monitoring
  • Prospective and retrospective clinical study data collection and CRF completion

Good Laboratory Practice services

Our Good Laboratory Practice (GLP) services include sponsor and contract laboratory facilities inspections; critical phase inspections; SOP development and review; data and final report audits; and adjunct QAU functions.

Good Manufacturing Practice services

Our Good Manufacturing Practice (GMP) services are principally related to clinical and nonclinical investigational products and include inspections of in-house and contracted drug product and drug substance manufacturing, packaging and labeling; process and scale-up validations; QA/QC systems evaluations; product complaint investigations; and logistics, storage and distribution audits.

Please call BioResearch Monitors to discuss how our quality assurance programs and services can add value and confidence to your research projects.

Make an enquiry

BioResearch Monitors, Inc.

201 Markham Hollow Road


New York 13159


United States of America

+1 315 696 8139 +1 315 668 6043 +1 315 696 8722

BioResearch Monitors Images

Products and Services


White Papers

Related Projects

Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms

Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.

25th May 2018

Bydureon® BCise™ for the Treatment of Type-2 Diabetes

Bydureon® BCise™ (exenatide extended-release) is an injectable suspension containing a glucagon-like peptide-1 (GLP-1) receptor agonist. 

4th May 2018

Ozempic (semaglutide) for the Treatment of Type 2 Diabetes

Ozempic® (semaglutide) is a glucagon-like peptide (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes in adults.

26th April 2018

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

22nd March 2018

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

27th July 2017

Haegarda for the Preventive Treatment of Hereditary Angioedema

Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

12th July 2017

Dinutuximab beta for the Treatment of Neuroblastoma

Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

18th May 2017

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).

17th April 2017

Zejula (niraparib) for the Treatment of Ovarian Cancer

Zejula™ (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.

9th April 2017

Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy

Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD).

16th February 2017

Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes

Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults.

1st September 2016

Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype

Cinqair is an injectable formulation of reslizumab developed by Teva Pharmaceuticals for the treatment of severe asthma and eosinophilic phenotype in adults.

11th May 2016

Anthim (obiltoxaximab) Injection for the Treatment of Inhalational Anthrax

Anthim (obiltoxaximab) is an injectable drug developed by Elusys Therapeutics for the treatment of inhalational anthrax caused by bacillus anthracis.

10th April 2016

Press Release

Regional Offices

BioResearch Monitors, Inc.

201 Markham Hollow Road


New York 13159


United States of America

+1 315 696 8139 +1 315 668 6043 +1 315 696 8722

Go Top